Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 8101–8150 of 35180
In connection with stepping down from his role as Chief Executive Officer of the Company, Mr. Magazine resigned from his position as a member of the board of directors of the Company (the “Board”), effective as of August 8, 2024.
on August 7, 2024, each of Mitchell Hollin and Michele Logan delivered notice of their resignation as a member of the Board and all committees thereof, subject to and contingent on the consummation of the Closing, pursuant to the terms of the Letter Agreement.
on August 7, 2024, each of Mitchell Hollin and Michele Logan delivered notice of their resignation as a member of the Board and all committees thereof, subject to and contingent on the consummation of the Closing, pursuant to the terms of the Letter Agreement.
appointed James Stavridis as a director of the Company, effective August 15, 2024.
On August 8, 2024, Michael C. Morgan notified the Company of his resignation as a Class I director of the Board of Directors of the Company and member of the Compensation and Human Capital Committee effective October 7, 2024.
tendered his resignation from the board of directors of the Company and as the Chief Business Officer of the Company.
On August 8, 2024, Michael C. Morgan notified the Board of Directors (the “Board”) and the Corporate Secretary of Stem, Inc. (the “Company”) of his resignation from the Board effective October 7, 2024 for personal reasons.
On August 7, 2024, Anthony Clark notified NorthWestern Energy Group, Inc. d/b/a NorthWestern Energy (Nasdaq: NWE) (the “ Company ”) of his intent to resign as a member of the Company's Board of Directors (the “ Board ”) effective December 31, 2024.
On August 4, 2024, Ronald B. Kalich resigned from the Board of Directors of Surmodics, Inc. (the “Company”). Mr. Kalich stated that he was resigning for health reasons.
On August 7, 2024, the Board appointed Cathleen Raffaeli to fill the vacancy that will be created by Ms. Cunningham’s retirement.
Kathleen Cunningham informed the Company that she would retire from the Company’s Board of Directors (the “Board”), effective August 19, 2024.
the Board filled the vacancy with Christine Cahill and appointed Ms. Cahill to serve on the Board effective immediately
Effective as of August 7, 2024, Mr. van Hoek resigned from the Board.
appointed Alan Liu to the Board as a Class II Director, to serve until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified
appointed Luis Sosa to the Board as a Class I Director, to serve until the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified
the Board of Directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”) appointed David Epstein, Ph.D. as a Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
Each of the Company’s directors, Randal W. Scott, PhD, Eric Aguiar, M.D., Jill Frizzley, Geoffrey S. Crouse, Christine M. Gorjanc, Kenneth D. Knight, Kimber D. Lockhart, Chitra Nayak, and William H. Osborne, and the Company’s remaining officers, including Kenneth D. Knight, Chief Executive Officer, Ana J. Schrank, Chief Financial Officer, Thomas R. Brida, General Counsel, Chief Compliance Officer and Secretary, and David B. Sholehvar, M.D., Chief Operating Officer, ceased being directors and officers of the Company on the Effective Date.
On August 6, 2024, Terry-Ann Burrell informed the Company’s board of her decision to resign as a member of the Company’s board and Chair of its Audit Committee, effective August 12, 2024.
appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships
appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships
On August 7, 2024, the Board of Directors (the “Board”) of Agenus elected Thomas L. Harrison to become a Class III director of Agenus with an initial term that expires at Agenus’s annual meeting of stockholders in 2027.
On August 5, 2024, Huili Shen tendered her resignation as a director and Secretary of QDM International Inc. (the "Company"), effective immediately.
To fill the vacancy created by Ms. Shen's resignation, the board of directors of the Company (the "Board") appointed Ms. Jun Du to serve as a director of the Board, effective as of August 5, 2024.
On August 5, 2024, Mark McCamish resigned as director of Rafael Holdings, Inc., effective immediately.
On August 5, 2024, Mark N. Stein, MD was elected as a director of Rafael Holdings, Inc. and elected as a member of the Company’s Board of Directors Audit, Compensation and Corporate governance committees.
Also on August 6, 2024, the Board appointed Mr. Tao-Chou Chang to fill the vacancy on and serve as a member of the Board
On August 6, 2024, Mr. Yao Chin Chen (Jim Chen) notified International Media Acquisition Corp. that he is resigning from the Board of the Company effective immediately.
On August 6, 2024, the Board appointed Mr. Hsu-Kao Cheng to fill the vacancy on and serve as a member of the Board
On August 7, 2024, the Board appointed Jill Frizzley and Matthew Kahn to the Company’s Board of Directors
On August 6, 2024, Akoustis Technologies, Inc. (the “Company”) and Jeffrey B. Shealy mutually agreed on Mr. Shealy’s resignation as the Company’s Chief Executive Officer and as a member of the Board of Directors (the “Board”) effective immediately.
On August 7, 2024, Suzanne Rudy informed the Company that she was resigning from the Board, effective immediately.
On August 2, 2024, Michelle Petock informed the Company that she was resigning from the Board, effective immediately.
On August 7, 2024, the Board appointed Jill Frizzley and Matthew Kahn to the Company’s Board of Directors
On August 7, 2024, Jeffrey McMahon informed the Company that he was resigning from the Board, effective immediately.
On August 6, 2024, Jerome C. Silvey, Jr., Bryan Summers, Andrew Blakeman and Marc Peperzak were appointed as members of the board of directors of the Company (the “Board”).
On August 6, 2024, Jerome C. Silvey, Jr., Bryan Summers, Andrew Blakeman and Marc Peperzak were appointed as members of the board of directors of the Company (the “Board”).
On August 6, 2024, Jerome C. Silvey, Jr., Bryan Summers, Andrew Blakeman and Marc Peperzak were appointed as members of the board of directors of the Company (the “Board”).
On August 6, 2024, Jerome C. Silvey, Jr., Bryan Summers, Andrew Blakeman and Marc Peperzak were appointed as members of the board of directors of the Company (the “Board”).
Following the consummation of the Business Combination, each of Xiaoma (Sherman) Lu, Jun Ge, Xinyue (Jasmine) Geffner and Kia Hong Lim was appointed to serve as a director of Pubco.
Following the consummation of the Business Combination, each of Xiaoma (Sherman) Lu, Jun Ge, Xinyue (Jasmine) Geffner and Kia Hong Lim was appointed to serve as a director of Pubco.
Following the consummation of the Business Combination, Cong Shi was appointed to serve as the sole director of Tristar.
Following the consummation of the Business Combination, each of Xiaoma (Sherman) Lu, Jun Ge, Xinyue (Jasmine) Geffner and Kia Hong Lim was appointed to serve as a director of Pubco.
Following the consummation of the Business Combination, each of Xiaoma (Sherman) Lu, Jun Ge, Xinyue (Jasmine) Geffner and Kia Hong Lim was appointed to serve as a director of Pubco.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.